Podcasts about rp1

Making strides against melanoma: how can medical oncologists and interventional oncologists join forces to deliver smarter, patient-centered care? In this episode of BackTable, Dr. Tyler Sandow, hosts Dr. Sunandana Chandra, medical oncologist at Northwestern, and Dr. Riad Salem, interventional oncologist at Northwestern to discuss the evolving management of advanced melanoma. --- This podcast is supported by an educational grant from Replimune. --- SYNPOSIS The doctors open the episode with an overview of melanoma and recent advances in its treatment, highlighting key trials such as DREAMseq and CheckMate 067. The discussion explores the shift from medical oncologist as solo primary providers to a dynamic, multidisciplinary approach to advanced cancer care—emphasizing cutting-edge treatments like immunotherapy and intratumoral oncolytic viruses. Dr. Salem shares practical insights on the procedural techniques of administering intratumoral oncolytics like Replimune, emphasizing the importance of thorough documentation and patient-centered care. The doctors also provide an overview of the ongoing IGNYTE-3 Trial, a Phase 3 study assessing the safety and efficacy of the oncolytic immunotherapy RP1 in combination with nivolumab for the treatment of advanced melanoma. The episode underscores the transformative potential of innovative melanoma treatments and the crucial role of integrated, team-based approaches in improving cancer patient outcomes. --- TIMESTAMPS 00:00 - Introduction03:48 - The Evolution of Melanoma Treatment: From Chemotherapy to Immunotherapy14:05 - The Role of Oncolytic Viruses in Melanoma Treatment20:14 - Interventional Radiology's Role in Cancer Treatment27:00 - Collaborative Approach to Cancer Care32:53 - Hyper Documentation and Communication Efficiency44:47 - Future of Intratumoral Oncolytics48:10 - Multidisciplinary Approach in Advanced Cancer Management51:46 - Conclusion and Final Thoughts --- RESOURCES DREAMseq Trial: Atkins MB, Lee SJ, Chmielowski B, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197. doi:10.1200/JCO.22.01763 CheckMate 067 trial: Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med. 2025;392(1):11-22. doi:10.1056/NEJMoa2407417

In today's episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. In our exclusive interview, Dr Pavlick discussed the rationale for investigating this combination in patients with advanced melanoma who have received prior immune checkpoint inhibition, key efficacy and safety findings from the phase 1/2 IGNYTE trial (NCT03767348), and where the future may be headed regarding the use of oncolytic viruses in melanoma.

Desakan evaluasi hingga menghentikan Makan Bergizi Gratis (MBG) terus mengemuka, menyusul terungkapnya sederet masalah dalam program unggulan Prabowo-Gibran ini. Yang terus berulang adalah kasus pelajar keracunan usai menyantap menu MBG, di antaranya terjadi di Cianjur, Jawa Barat, Sukoharjo, Jawa Tengah, hingga Bombana, Sulawesi Tenggara. Di Cianjur, bahkan, kasus itu ditetapkan sebagai Kejadian Luar Biasa (KLB).Komentar Kepala Badan Gizi Nasional (BGN) Dadan Hindayana makin menyulut kemarahan publik, karena menganggap kasus keracunan masih terbilang kecil, yakni 0,5 persen dari total 2 juta penerima manfaat MBG.Pertengahan April lalu, program ini juga digoyang kasus tutupnya dapur MBG di Kalibata, Jakarta, karena ada tunggakan pembayaran hampir Rp1 miliar.Program MBG memang mendapat banyak sorotan karena menyedot anggaran negara yang sangat besar. Tak sedikit yang mendukung program ini, tetapi sangsi dengan pengelolaan dan implementasinya.Sejumlah lembaga melakukan pemantauan sejak kick off MBG 6 Januari 2025. Apa saja temuan dan evaluasinya? Apakah program ini harus dihentikan atau ditunda?Ruang Publik akan membahasnya bersama Founder dan CEO Center for Indonesia's Strategic Development Initiatives (CISDI), Diah Satyani Saminarsih dan Staf Divisi Riset & Advokasi Indonesia Corruption Watch (ICW), Eva Nurcahyani.

Pusat Pelaporan dan Analisis Transaksi Keuangan (PPATK) memaparkan, perputaran uang dari aktivitas judi online (judol) 2025 mencapai Rp1.200 triliun. Dari angka itu, Polri dan Kementeri dan Komunikasi dan Digital (Komdigi) dapat menekan hingga Rp500 triliun.

Seorang kasir perusahaan perkebunan kelapa sawit nekad mencuri uang gaji karyawan lebih dari Rp1 miliar di Pekanbaru, Riau. Uang hasil kejahatan ini digunakan untuk membayar utang dan bermain judi online.

SILABUSPPATK ungkap perputaran uang judi online pada 2025 diperkirakan tembus Rp1.200 trilyun, apa yang harus dilakukan? bersama:Pakar hukum pidana Univ Tarumanegara, Heri FirmansyahSosiolog Universitas Katolik (Unika) Soegijapranata Semarang, Hermawan Pancasiwi

Indeks Harga Saham Gabungan (IHSG) pada pembukaan perdagangan setelah libur panjang Lebaran, Selasa, 8 April 2025, langsung ambruk ke posisi 5.914,28.Mengacu data RTI yang terekam hingga pukul 09.05 WIB, IHSG tercatat jatuh ke level 5.912,06 atau turun sebanyak 598,55 poin setara 9,19 persen.Hal ini membuat pasar saham Indonesia langsung trading halt, yakni penghentian sementara perdagangan saham yang terjadi ketika IHSG mengalami penurunan yang signifikan.Adapun sebanyak 552 saham emiten melemah pada perdagangan pagi ini. Sementara, hanya sembilan saham yang berhasil menguat dan 65 saham yang stagnan.Untuk sementara, total transaksi yang tercatat hingga pukul 09.05 WIB sebanyak Rp1,92 triliun dengan total saham yang diperdagangkan 1,59 miliar saham.

Welcome to this exciting episode of The Edge of Show, your gateway to the Web3 revolution! Join us as we dive deep into the latest innovations in blockchain, cryptocurrency, NFTs, and the metaverse, featuring special guests. In this episode, we explore the groundbreaking launch of the world's first 3D browser with RP1, designed to revolutionize how we interact with the digital world. Sean Mann and Dean Abramson share insights on their journey from vision to reality, discussing the technology that allows for unprecedented scalability and user experience in the metaverse.Additionally, we also sat with Yumin Xia, co-founder and CTO of Galxe, to talk about their viral reward platform and the challenges of user retention in the crypto space. Yimin shared insights on building a new blockchain, GravityChain, aimed at simplifying user interactions across multiple blockchains.Finally, Will Hennessey from Alchemy discusses their recent $5 million initiative to onboard new users into crypto through account abstraction and rollups, making the user experience seamless and accessible.Tune in for an engaging discussion filled with insights from industry leaders and learn how you can get involved in the future of Web3! Support us through our Sponsors! ☕

Bank Indonesia mencatat kredit konsumsi tumbuh 9,4% per Februari 2025, mencapai Rp2.208,5 triliun. Kredit multiguna menjadi pendorong utama dengan Rp1.265 triliun, diikuti KPR Rp799,8 triliun, dan kredit kendaraan Rp143,1 triliun. Secara keseluruhan, kredit perbankan naik 9% menjadi Rp7.684 triliun.

Kasus dugaan korupsi yang menyeret sejumlah petinggi Pertamina membuat geger masyarakat. Bukan hanya tuduhan Pertamax oplosannya, namun juga nilai kerugian yang ditaksir mencapai hampir Rp1.000 triliun. Kasus ini menjadi kasus korupsi terbesar dari jumlah kerugian yang berhasil dibongkar aparat.Walau pemberantasan korupsi terus dilakukan dan fakta integritas serta antikorupsi sudah ditandatangani, nyatanya masih saja banyak pejabat di republik ini yang terjerat korupsi. Bahkan, nilai korupsi semakin besar dari waktu ke waktu, dari puluhan hingga ratusan triliun rupiah.Apa yang salah dengan negara ini ketika budaya korupsi terus merajalela? Dan, mengapa koruptor belum ada dihukum mati?

This week, we were all over the place with a bunch of different designs and experiments. After last week's analysis of the TLV320DAC3100, we made some updates to the design and re-booked prototype PCBs. We also designed a triple-matrix bonnet: with our latest work on getting HUB75 RGB matrices working on the Raspberry Pi 5, we can now do matrix control on the latest Pi 5 chip. But we're limited by the RP1 chip, so to get big displays going, we'll need multiple strands—these don't use significantly more bandwidth because half of the pins are shared. Finally, we ended the week by getting another older prototype working: the SAM-M8Q is an entry-level all-in-one GPS from u-blox. It comes with both UART and I2C interfaces, plus a built-in antenna, so it's ready to go out of the box. The NMEA interface is trivial, but we also wanted to try out the UBX interface, and thankfully, Claude 3.7 was able to vibe-code it for us in a jiffy.

Presiden AS Donald Trump siap sampaikan pidato di hadapan Kongres hari Selasa (4/3), di mana isu Gaza dan Ukraina diperkirakan akan disinggung. Sementara di Indonesia, Presiden Prabowo Subianto akan menggelontorkan Rp1-2 triliun per bulan untuk program Makan Bergizi Gratis mulai Maret.

Charlie, Ted, and Rony welcome Sean Mann, CEO of RP1, whose Metaverse browser can support hundreds of thousands of unique users in a spatial environment. It's earning week in the tech world and the outlook for 2025, after two years of hypergrowth, is downright conservative. Love for Meta's money printing machine continued, despite continued losses on its Metaverse ambitions. Apple's discontinuing AR glasses. Or are they? And Alexa is back. Using RP1's browser, users can share spatial environments, including 1:1 maps of the physical world, on any browser, including VR. Charlie says the MR demo of RP1 that he showed him on Thursday was the most like the mixed reality described in "Snow Crash" he has ever seen. Thank you to our sponsor, Zappar!Don't forget to like, share, and follow for more! Follow us on all socials @ThisWeekInXR!https://linktr.ee/thisweekinxr Hosted on Acast. See acast.com/privacy for more information.

This week's EYE ON NPI is an EYE ON A PI - it's the Raspberry Pi Compute Module 5 (https://www.digikey.com/en/product-highlight/r/raspberry-pi/raspberry-pi-compute-module-5), the latest update to the easily embeddable mini modules that make industrial developers happy by giving them all the power of a Pi 5 in a ready-to-go pluggable solution. The Raspberry Pi computer launched with the goal of bringing low cost computing to the education market (https://www.bbc.co.uk/blogs/thereporters/rorycellanjones/2011/05/a_15_computer_to_inspire_young.html) and through the Pi Foundation (https://www.raspberrypi.org/) they still have that charitable goal (https://static.raspberrypi.org/files/about/RaspberryPiFoundationStrategy2025.pdf) while also spinning off the manufacturing/sales company into the Trading Company which went public this year (https://www.raspberrypi.org/blog/what-would-an-ipo-mean-for-the-raspberry-pi-foundation/). The first few Raspberry Pi computers were 'all in one' style (https://www.adafruit.com/product/1344), with power, GPIO, Video and Audio output, USB, Ethernet, and Micro SD card storage (https://raspi.tv/2018/new-raspberry-pi-family-photo-including-pi3a-plus-zero-wh). Eventually enough folks asked for an enclosure-friendly version that would allow an "I/O" board to be designed with the ports in a different arrangement - the big-sized-Pis have them arrayed over 3 sides. To solve this conundrum, and to satisfy the growing industrial/commercial market, the Pi engineers designed the Compute Module 1 which is still available (https://www.raspberrypi.com/products/compute-module-1/). This clever SODIMM packaged board has all the GPIO and peripheral pins on a plug-in connector so you can slot it into an existing design securely and easily - SODIMM sockets (https://www.digikey.com/short/rz9cdjrn) come both vertical and horizontal. This was later updated to the CM3 and CM3+ (https://www.digikey.com/en/products/detail/raspberry-pi/SC0149/9866293) which was on par with the Pi 3 instead of the Pi 1, with significantly higher computational power. However, perhaps because they wanted a more compact module, or to support high-frequency signals better, the next generation of Compute Module 4's (https://www.digikey.com/short/wffzdn0b) came in a flat rectangular shape with dual 100-pin Hirose contacts. (https://www.digikey.com/short/5m8djf0t) Another nice thing that happened with the CM4 is it became available in dozens of configurations: 1/2/4/8 GB RAM, SD or 8/16/32GB MMC, and with or without WiFi/BLE/BT. This allowed commercial users to go with the 'lowest cost option' needed to fulfill their requirements - whereas the Pi 4 comes in only 3 or 4 RAM options (https://www.digikey.com/short/4pn5vw24). The ready-to-go software - no kernel compiling or OpenWRT configuration required! Long-term hardware support and low prices pushed the CM4 into more and more designs. Which brings us to the NPI of the week, the Compute Module 5 (https://www.digikey.com/en/product-highlight/r/raspberry-pi/raspberry-pi-compute-module-5)! The CM5 is a big upgrade, with quad A76s at 2.4GHz for a 2x computing upgrade, increased RAM options of up to 16G, increased MMC option of 64GB, USB 3.0 ports, PCIe and RP1 hardware interfacing with PIO support (https://www.raspberrypi.com/news/piolib-a-userspace-library-for-pio-control/). If you have an existing CM4 design, you can easily upgrade or update to the new hotness. If you're new to integrating Raspberry pi, then while you may think of the Pi as a hobby/school computer, that isn't necessarily true anymore with 72% of Pi computers sold going into commercial/industrial use (https://investors.raspberrypi.com/ipo/documents/1). That means you can be confident that you'll get consistent pricing and availability for a long time so that you can work on designing the rest of your product for the CM series to plug into. And like the CM4, the CM5 is available in a variety of configurations and prices, from $45 to $135. Raspberry Pi Compute Module 5's are currently only available for pre-order (https://www.digikey.com/en/product-highlight/r/raspberry-pi/raspberry-pi-compute-module-5) , with estimated ship times in Q1 of 2025 to DigiKey - and the moment DigiKey gets some in stock, they'll ship your pre-order instantly so you can get integrating with the Pi ecosystem the very next day. Don't wait till release day because they'll sell out instantly! Instead, when you pre-order from DigiKey, your order goes into a queue and you'll get first-come-first-served prioritization. See more on DigiKey https://www.digikey.com/short/47t12drj

Ladyada tasked Jepler with exploring the new libPIO for Raspberry Pi 5 computers: this gives us access to the RP1 chip so that we can run custom PIO state machines on the GPIO pins. A common use case is NeoPixels, because of the tight timing requirements of the WS281x LEDs. Here is our first light test that shows it is possible... Visit the Adafruit shop online - http://www.adafruit.com ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ ----------------------------------------- #raspberrypi #adafruit #pio

Hot off the PIO-presses, our resident Jepler created a Python binding for the Raspberry Pi 5 that lets us use the RP1 chip (https://www.raspberrypi.com/news/rp1-the-silicon-controlling-raspberry-pi-5-i-o-designed-here-at-raspberry-pi/) on the 5/500 series boards to drive Neopixels using PIO. This is great because we can now use Neopixels (https://www.adafruit.com/category/168) and friends on the latest Pi boards, and we can use any pin because PIO is not limited by underlying peripherals. You do need the latest kernel and firmware, so it is not quite ready for prime-time, but once piolib (https://github.com/raspberrypi/utils/tree/master/piolib) is more readily available, we'll be able to have folks test this out. Visit the Adafruit shop online - http://www.adafruit.com ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ ----------------------------------------- #raspberrypi #NeoPixels #Python

Mafia Kasus, Bukti Keadilan Kian Tergerus Oleh. Dyah Pitaloka(Tim Penulis Inti NarasiPost.Com) Voice over talent: Dewi Nasjag NarasiPost.Com-Dilansir dari metro.tempo.co, Kejaksaan Agung menetapkan Zarof Ricar, mantan pejabat MA, sebagai tersangka kasus suap terkait perkara Gregorius Ronald Tannur. Zarof ditangkap sehari sebelumnya di Bali dan diduga menjadi perantara antara pengacara Tannur, Lisa Rachmat, dengan hakim. Lisa menjanjikan Rp5 miliar kepada hakim, sementara Zarof menerima Rp1 miliar. Naskah selengkapnya: ⁠https://narasipost.com/opini/11/2024/mafia-kasus-bukti-keadilan-kian-tergerus/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipostx

Kabinet Gemoy, Beban APBN Gemoy Oleh. Vega Rahmatika Fahra, S.H.(Kontributor NarasiPost.Com) Voice over talent: Dewi Nasjag NarasiPost.Com-Pemerintahan baru yang dipimpin oleh Presiden Prabowo Subianto dan Wakil Presiden Gibran Rakabuming Raka menimbulkan banyak perhatian dari masyarakat, khususnya terkait jumlah menteri dan wakil menteri yang ditunjuk. Dengan total 49 menteri dan 59 wakil menteri, kabinet ini disebut-sebut sebagai kabinet gemoy (gemuk) yang berpotensi menguras Anggaran Pendapatan dan Belanja Negara (APBN) hingga Rp1,95 triliun. Kenaikan anggaran yang signifikan ini menimbulkan berbagai pertanyaan tentang efisiensi dan prioritas penggunaan anggaran pemerintah. (cnnindonesia.com, 17-10-2024) Naskah selengkapnya: ⁠https://narasipost.com/opini/10/2024/kabinet-gemoy-beban-apbn-gemoy/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipostx

Wacana penyesuaian tarif KRL atau commuter line Jabodetabek kembali mengemuka. Pemerintah ingin mengubah skema subsidi KRL menjadi berbasis Nomor Induk Kependudukan (NIK). Wacana ini mengundang kritik karena tarif bakal naik untuk kalangan tertentu. Padahal, daya beli masyarakat tengah melemah seiring lesunya ekonomi. Apalagi, layanan KRL juga dinilai belum optimal. Kalangan yang pro memandang wacana penyesuaian tarif KRL sebagai hal wajar. Sebab, sejak 2016 tarif dasar KRL belum berubah, yakni Rp3.000 untuk 25 km pertama, dan penambahan Rp1.000 untuk 10 km berikutnya. Bagaimana menjembatani pro-kontra ini? Apakah tarif KRL perlu dinaikkan? Tepatkah penerapan skema subsidi transportasi berbasis NIK? Kita bincangkan bersama Wakil Ketua Pemberdayaan dan Pengembangan Wilayah Masyarakat Transportasi Indonesia (MTI) Pusat, Djoko Setijowarno dan Jubir KRLMania Gusti Raganata. *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

Banyak orang percaya investasi emas bisa jadi aset aman atau safe haven, yang melindungi saat aset lain berfluktuasi. Ternyata, logam mulia ini tidak hanya sebagai penyimpan nilai, tetapi juga memberikan return. Apalagi dengan kondisi dunia yang masih tidak pasti, nilai emas semakin tinggi. Jika dibandingkan dengan aset investasi lainnya dalam setahun terakhir, kinerja emas justru unggul. Misalnya, harga beli emas Treasury sudah naik 29%, dan per 28 Mei 2024 mencapai Rp1.257.706 per gram. Apakah ini pertama kalinya emas unggul dari aset lain atau sebelumnya juga pernah seperti ini? Temukan jawabannya di Podcast Bareksa Insight Eps.22 kali ini bersama Andreas Santoso, CEO Treasury. Install sekarang! https://bareksa.onelink.me/bLEI/YTBareksa

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

“Talladega Nights gets a lot better after you've seen Rise of Skywalker, that's for sure” The Panel of Peril run and gun all your favourite film and video games characters in one fluid motion, before removing their VR headset in order to watch this week's film. That film is Ready Player One (Steven Spielberg, 2018), and they are joined by Kevin and Jason from KJ & A Podcast! Wade Watts (Tye Sheridan) is just like most people in the year 2045; he gets through the day any way he can before escaping to the virtual reality of the OASIS to enact his fantasies. But when the now-deceased VR creator Halliday (Mark Rylance) challenges the players to find his hidden easter egg, and gain control of the OASIS, the virtual race is on – and it will be fought to the literal death. Watch the trailer here: https://www.youtube.com/watch?v=cSp1dM2Vj48 ********PLOT SPOILER ALERT******** Nicolas Sorrento (Ben Mendelsohn) plans to find the egg for his own nefarious ends. He will monetise the OASIS, restricting access for those on the lowest incomes, thereby turning a dream playground into a corporate nightmare. Starring the likes of (friend of the pod) Batman, Chun Li, Chucky and Mecha Godzilla, RP1 is certainly a film with lots of stuff to point at when you spot it. Just what did the panel think of this week's movie, pray tell? How can they improve upon Sorrento's OASIS-hijacking plan? And who will be christened this week's most diabolical? https://twitter.com/diabolicalpod https://www.instagram.com/diabolicalpod/ https://www.facebook.com/diabolicalpod Email diabolicalpod@gmail.com

Pasar Kripto kian menggeliat di 2024 didorong momentum pengurangan pasokan baru atau halving day Bitcoin. Harga Bitcoin sudah pecah rekor, melampaui US$68.000 atau lebih dari Rp1 miliar. Antusiasme pasar di tanah air terlihat dari jumlah investor kripto per Februari 2024 yang mencapai 19 juta orang, berdasarkan data Badan Pengawas perdagangan Berjangka Komoditi (Bappebti). Jumlah ini naik dari Januari yang tercatat 18,83 juta orang. Besaran transaksinya pun melonjak dari Rp21,57 triliun pada Januari menjadi sekitar Rp50 triliun lebih. Bagi anda yang tertarik untuk berinvestasi di kripto, baiknya jangan karena FOMO, karena aset ini termasuk kategori high risk. Nah, apa saja hal-hal mendasar yang harus diketahui sebelum invest di kripto? Bagaimana perencanaan keuangannya? Strategi seperti apa yang cocok diterapkan agar investasi kripto aman dan cuan? Kita bahas topik seru ini di Ruang Publik KBR bersama Financial Market Specialist, Lucky Bayu Purnomo dan Rieka Handayani, VP PR & Marketing Tokocyrpto. *Kami ingin mendengar saran dan komentar kamu terkait podcast yang baru saja kamu simak, melalui surel ke podcast@kbrprime.id

*Apologies for the poor audio quality on Taylor's mic as we experienced some technical difficulties during recording* On this episode, Kyle and Taylor are joined by Enrico to discuss relief pitchers. Topics discussed include whether Emmanuel Clase should be RP1 in dynasty, what to do with Felix Bautista, and why Evan Phillips and Clay Holmes are criminally underrated. Thank you for listening and be sure to follow us on Twitter/X at (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/GreatDebateTC⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/_sonny_50⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) where the ADP will be posted if you want to follow along. We are excited to now be part of Prospects Live! Be sure to follow the account on Twitter/X (⁠⁠⁠https://twitter.com/ProspectsLive⁠⁠⁠). Consider subscribing to the Patreon (⁠⁠⁠https://www.patreon.com/prospectslive⁠⁠⁠), starting at just $5 a month, to get access to amazing tools and content such as: PLive+ Peak Projections Top 1000 Dynasty Rankings (with Auction Values and League Analyzer) Top 500 Prospect Rankings Trade Analyzer Top 30 team scouting reports with added fantasy context Daily sheets (including for Spring Training, AFL, and LIDOM) Private discord channels for tier 70 and up. Additional written and audio content, including more from us! Also check out the Fantasy Baseball Discord to interact with us and many other great fantasy/dynasty/prospect minds (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://discord.gg/fantasybaseball)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Finally please rate and review the podcast if you have not done so already as that would really help us out.

Dalam rangka perayaan ulang tahun ke-128, BRI mengadakan BRImo FSTVL dan berkolaborasi dengan Swarna Land yang menampilkan konser musik Nadin Amizah bersama The Secret, Happy Soda, dan Brilian Band pada Sabtu 09 Desember 2023. Tidak hanya, para pengguna BRImo bisa mendapatkan doorprize dari BRI. Pengunjung hanya perlu scan QRIS yang telah disediakan saat entry gate menggunakan BRImo sebesar Rp1 dan dapatkan kupon doorprize yang akan diundi untuk mendapatkan hadiah selama event berlangsung. Pengunjung juga bisa mendapatkan kupon belanja dengan menukarkan 2 botol plastik di booth BRI. Konser Nadin Amizah ini dilaksanakan di pool Pangeran Beach Hotel Padang.

Headline News MetroTV Edisi 2273 kali ini membahas harga emas 24 karat cetakan PT Aneka Tambang Tbk (Antam) turun hari ini. Mengacu laman Logam Mulia, Selasa, 31 Oktober 2023 harga emas Antam turun Rp4.000 dari Rp1,135 juta menjadi Rp1,131 juta untuk ukuran satu gram.

James Adams and Liam Fraser of the Raspberry Pi hardware team once again join Chris to talk about the RP1 custom silicon on the Raspberry Pi 5

This week's Electromaker Show is now available on YouTube and everywhere you get your podcasts! Welcome to the Electromaker Show episode 124! This week our product of the week is the Arduino Nano ESP32 - yes, everyone's favorite SoC on the world's most loved development board. We also find out more about the RP1 from Raspberry Pi, see an amazing new rotary encoder devboard from M5Stack, and return to Crowd Supply for Funding Website Things! Tune in for the latest maker, tech, DIY, IoT, embedded, and crowdfunding news stories from the week.   Watch the show! We publish a new show every week. Subscribe here: https://www.youtube.com/channel/UCiMO2NHYWNiVTzyGsPYn4DA?sub_confirmation=1 We stock the latest products from Adafruit, Seeed Studio, Pimoroni, Sparkfun, and many more! Browse our shop: https://www.electromaker.io/shop Join us on Discord! https://discord.com/invite/w8d7mkCkxj​ Follow us on Twitter: https://twitter.com/ElectromakerIO Like us on Facebook: https://www.facebook.com/electromaker.io/ Follow us on Instagram: https://www.instagram.com/electromaker_io/ Featured in this show: Product of the Week: Arduino Nano ESP32 More Pi 5 development goodies: RP1 ESP32 based Gesture remote MQTT Anywhere Giveaway Winner announced! Crowd Supply Lightning Round: PolyKybd AI in a box: Offline LLM assistant HaxaPhone Update! Mini robot Mic Swarms: M5 Stack rotary encoder screen with ESP32

The Raspberry Pi 5 is the latest version of one of the world's most popular computers. It was just announced on Thursday and will be released on October 23rd. The new model comes in two versions, a 4GB and an 8GB model, priced at $60 and $80 respectively. Compared to the previous Raspberry Pi 4 models, these prices are only $5 more.Raspberry Pi 5 is faster and improvedOne of the main improvements of the Raspberry Pi 5 is its faster processing power. It features a new Broadcom system on a chip (SOC) with a quad-core CPU running at 2.4GHz and a quad-core GPU. The previous model had a CPU running at 1.8GHz and a GPU with lower clock speed. The new SOC allows for overclocking up to 3GHz, providing even better performance.The GPU of the Raspberry Pi 5 is a video core seven GPU with a stock speed of 800MHz, compared to 500MHz on the previous model. Although overclocking the GPU did not result in significant graphics improvements, the overall performance of the device is noticeably faster for various tasks.Another notable improvement is the inclusion of the RP1 chip, designed by Raspberry Pi, which controls the IO for the USB3 ports, USB2 ports, and Ethernet port. This allows for higher throughput, resulting in faster read and write speeds for USB devices. The Ethernet port remains a gigabit port, providing similar speeds to the previous model. The Wi-Fi card, however, has a faster interconnect to the CPU, resulting in double or more than double the speed of the Raspberry Pi 4 under good conditions.The Raspberry Pi 5 does not come with a fan, but it is recommended to use one to prevent overheating. Without a fan, the device can reach temperatures up to 80 degrees Celsius, which is the throttle point. The official fan, specifically designed for this layout, is available for around $6. It can be easily mounted on the device using the dedicated mounting holes and four-pin header.Overall, the Raspberry Pi 5 offers significant improvements in processing power, graphics performance, and IO throughput compared to its predecessor. It is a highly anticipated computing device that provides faster and improved capabilities for various applications.New Raspberry Pi features power buttonOne of the standout features of the new Raspberry Pi 5 is the addition of a power button, which is a first for the Raspberry Pi line. This power button allows users to easily turn the device on and off without having to unplug it from the power source. However, it is important to note that the power button is not a hard cutoff switch, but rather a soft momentary button that initiates shutdown when pressed.The addition of a power button may not seem like a significant feature, but it offers several benefits. Firstly, it eliminates the need to unplug the device to turn it off, which can be inconvenient and potentially lead to the corruption of the SD card. With the power button, users can safely shut down the Raspberry Pi without the risk of data loss or corruption.Additionally, the power button allows for easier and quicker boot-up times. When the Raspberry Pi is plugged into the power source, it automatically boots up, eliminating the need to manually turn it on. This can be particularly useful in situations where the device needs to be constantly powered on and off, such as in a server setup.Furthermore, the power button is programmable, meaning that users can customize its functionality to suit their needs. Currently, pressing the power button brings up the shutdown menu on the screen. However, it is possible to program it to perform other actions, such as initiating a specific command or launching a particular application. This programmability adds an extra layer of versatility to the Raspberry Pi 5 and allows users to tailor its functionality to their specific requirements.

Prejuicios por el fondo de tus videollamadas / Intel Irlanda arranca los 4 nm / Raspberry Pi 5 por sorpresa / Redada de Nvidia en Francia / Diseña tu propia galaxia Patrocinador: Por fin llega a los cines The Creator, una de las películas de ciencia ficción más esperada. Se estrena el 29 de septiembre y que no te puedes perder por nada del mundo. Dirigida por Gareth Edwards (su primera película tras Rogue One), estoy seguro que The Creator será un clásico instantáneo. — ¿Has visto ya el trailer? Prejuicios por el fondo de tus videollamadas / Intel Irlanda arranca los 4 nm / Raspberry Pi 5 por sorpresa / Redada de Nvidia en Francia / Diseña tu propia galaxia

Pemerintah dengan DPR RI menyepakati target penerimaan pajak tahun 2024 sebesar Rp1.988,8 triliun.

Drs Sapna P. Patel and Kim A. Margolin sift through the data from studies presented at recent conferences, including the KEYNOTE-942 and RP1 IGNYTE studies. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/989036). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) https://classic.clinicaltrials.gov/ct2/show/NCT03897881?term=Keynote-942&draw=2&rank=1 A Personalized Cancer Vaccine, mRNA-4157, Combined With Pembrolizumab Versus Pembrolizumab in Patients With Resected High-Risk Melanoma: Efficacy and Safety Results From the Randomized, Open-Label Phase 2 mRNA-4157-P201/Keynote-942 Trial https://www.abstractsonline.com/pp8/#!/10828/presentation/10243 Distant Metastasis-Free Survival Results From the Randomized, Phase 2 mRNA-4157-P201/KEYNOTE-942 Trial https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA9503 Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/36856617/ Pembrolizumab Versus Placebo as Adjuvant Therapy in Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase 3 KEYNOTE-716 Study https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA9505 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) https://www.clinicaltrials.gov/study/NCT03767348?term=Study%20of%20RP1%20Monotherapy%20and%20RP1%20in%20Combination%20With%20Nivolumab%20(IGNYTE)&rank=1 Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/33803762/ Randomized, Double-blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/35998300/ Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma https://oncologypro.esmo.org/meeting-resources/esmo-congress/phase-i-study-of-fianlimab-a-human-lymphocyte-activation-gene-3-lag-3-monoclonal-antibody-in-combination-with-cemiplimab-in-advanced-melanoma Significant Durable Response With Fianlimab (Anti-LAG-3) and Cemiplimab (Anti-PD-1) in Advanced Melanoma: Post Adjuvant PD-1 Analysis https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.9501?af=R Relatlimab and Nivolumab Versus Nivolumab in Untreated Advanced Melanoma https://pubmed.ncbi.nlm.nih.gov/34986285/ BRAF and MEK Inhibition in Melanoma https://pubmed.ncbi.nlm.nih.gov/25648338/ Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations https://pubmed.ncbi.nlm.nih.gov/29644214/ Society for Immunotherapy of Cancer (SITC) Consensus Definitions for Resistance to Combinations of Immune Checkpoint Inhibitors https://pubmed.ncbi.nlm.nih.gov/36918224/ RECIST 1.1 – Update and Clarification: From the RECIST Committee https://pubmed.ncbi.nlm.nih.gov/27189322/ Histopathological Features of Complete Pathological Response Predict Recurrence-Free Survival Following Neoadjuvant Targeted Therapy for Metastatic Melanoma https://pubmed.ncbi.nlm.nih.gov/32739408/

Melepas Jerat Utang Ribawi dengan Solusi Hakiki Oleh. Trisna Abdillah(Kontributor NarasiPost.Com) Voice Over Talent: Dewi Nasjag NarasiPost.Com-Jelang tahun pemilu 2024, lonjakan jumlah utang pemerintah kembali menjadi polemik. Mantan Wakil Presiden RI Jusuf Kalla (JK) menyebut jumlah utang melonjak tajam di masa pemerintahan Presiden Joko Widodo (Jokowi). JK mengatakan dalam setahun negara membayar bunga dan utang lebih dari Rp1.000 T terbesar dalam sejarah Indonesia sejak kemerdekaan. Jika hal ini berlangsung terus menerus, ia menilai utang pemerintah yang tinggi akan menjadi bom waktu dan membebani pemerintah berikutnya, sebab beban utang dan bunga berimbas semakin menyempitnya ruang fiskal APBN. (Kompas.com, 5/6/2023) Menteri Keuangan (Kemenkeu) Sri Mulyani tidak menepis ataupun mengiyakan keterangan JK. Ia hanya menegaskan bahwa utang pemerintah masih di batas aman dan bisa ditangani oleh negara. Naskah selengkapnya: https://narasipost.com/2023/06/08/melepas-jerat-utang-ribawi-dengan-solusi-hakiki/opini/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipost

Like father like son, Rafael Alun-Mario Dandy, Bapak-anak kompak pakai baju tahanan. Rafael Alun tersangka korupsi sedangkan anaknya Mario Dandy tersangka penganiayaan. Menpora baru kepala BNPT juga baru. Setelah resmi dilantik presiden Jokowi, Dito Ariotedjo sebagai Menpora tentu punya PR besar. Begitu juga dengan Komjen Ryko Amelza yang kini bertugas sebagai kepala BNPT. Selamat bekerja bapak-bapak. Pemerintah Italia menerapkan kebijakan denda sebesar €100.000 atau sekitar Rp1,6 miliar bagi warganya yang pakai bahasa Inggris dan bahasa asing lainnya dalam acara resmi.

Kementerian Keuangan mencatat penerimaan pajak hingga September 2022 mencapai Rp1.310,5 triliun atau melonjak 54,2 persen dibanding periode yang sama pada tahun lalu.

DJP mencatat realisasi penerimaan pajak hingga Oktober 2022 mencapai Rp1.448,17 triliun atau 97,5 persen dari target.

Usulan Kenaikan Bantuan Parpol di Tengah Kesulitan Rakyat, Pantaskah? Oleh. Sri Retno Ningrum (Kontributor Narasi Post.Com) Voice over talent: Maya Rohmah NarasiPost.Com-Baru-baru ini dikabarkan pemerintah melalui Menteri Dalam Negeri, Tito Karnavian, mengusulkan kenaikan bantuan dana Partai Politik (parpol) tiga kali lipat, sehingga per suara Rp1.000,00 menjadi Rp3.000,00 per suara. Sementara itu, Komisioner KPU (Komisi Pemilihan Umum), Hadar Nafis Gumay, mengatakan bahwa kenaikan bantuan parpol di tengah kondisi krisis keuangan dan kenaikan BBM yang dirasakan rakyat kurang tepat apalagi naik sampai tiga kali lipat. (Republika.com, 22/9/2022) Apabila kita amati usulan pemerintah tersebut di tengah kesulitan yang menimpa rakyat akibat diterapkannya sistem kapitalisme memang menyakiti hati rakyat. Padahal, setiap harinya rakyat selalu dihadapkan pada harga barang yang melambung tinggi, kenaikan listrik, gas dan kemarin kenaikan harga BBM yang naik sekitar 30 persen. Sungguh itu membuat rakyat menderita. Akan tetapi, di sisi lain pemerintah malah mengusulkan kenaikan bantuan parpol hingga tiga kali lipat. Miris! Selain itu, perlu diketahui bahwa partai politik yang ada dalam sistem demokrasi mustahil akan menampung aspirasi rakyat, sebaliknya mereka bekerja untuk kepentingannya sendiri. Mereka hanya mendekati rakyat di saat pemilihan umum untuk mendapatkan suara banyak dan dapat ikut melegalkan UU. Akan tetapi, setelah mereka berkuasa rakyat dilupakan. Apalagi ketika terjadi koalisi partai, visi dan misi partai dihilangkan demi ambisi kekuasaan. Walhasil, perlu dipertanyakan apakah dengan naiknya bantuan partai dapat memperbaiki nasib rakyat? Kemudian pantaskah hal tersebut dilakukan? Naskah selengkapnya: https://narasipost.com/2022/10/17/usulan-kenaikan-bantuan-parpol-di-tengah-kesulitan-rakyat-pantaskah/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipost

Polemik Dana Pensiun, Bebankah? Oleh. Afiyah Rasyad (Kontributor NarasiPost.Com dan Aktivis Peduli Umat) Voice over talent: Sofia Ariyani NarasiPost.Com-Amboi, selama ini status Pegawai Negeri Sipil (PNS) seakan menjadi primadona. Betapa tidak, setelah berakhir masa kerjanya, mereka digadang-gadang tetap bisa mendapat kehidupan layak dengan dana pensiun yang memadai dari negara. Kuota PNS diperebutkan setiap ada tes CPNS oleh seluruh kalangan masyarakat. Perubahan Skema Dana Pensiun Baru-baru ini, tersiar kabar tak sedap yang beredar di tengah masyarakat. Kabar itu membuat PNS mulai waswas. Sebab, dana pensiun yang terlaksana selama ini dianggap membebani negara. Dalam rapat kerja bersama Komisi XI DPR, Menteri Keuangan Sri Mulyani menyebutkan bahwa skema penyaluran dana pensiun bagi para PNS telah membebani negara, jumlahnya mencapai Rp2.800 triliun. Dia memandang skema tersebut perlu diubah (cnbcindonesia.com, 27/8/2022). Selama ini, pemberian dana pensiun menggunakan skema pay as you go. Pemerintah yang menyisihkan uang untuk dana pensiun. “Totalnya Rp2.800 triliun, estimasi tahun lalu Rp900 triliun dari pusat dan Rp1.900 triliun dari daerah, dibagi beberapa provinsi dan kabupaten,” ungkap Dirjen Anggaran Kemenkeu Isa Rachmatarwata (cnbcindonesia.com, 25/8/2022). Naskah selengkapnya: https://narasipost.com/2022/09/04/polemik-dana-pensiun-bebankah/ Terimakasih buat kalian yang sudah mendengarkan podcast ini, Follow us on: instagram: http://instagram.com/narasipost Facebook: https://www.facebook.com/narasi.post.9 Fanpage: Https://www.facebook.com/pg/narasipostmedia/posts/ Twitter: Http://twitter.com/narasipost

Gubernur Papua Lukas Enembe ditetapkan tersangka korupsi. KPK menyebut Enembe diduga menerima gratifiksi sebesar Rp1 miliar. Selain itu, PPATK menduga ada aliran dana kasino judi Rp560 miliar Lukas Enembe. Uganda telah mengumumkan kejadian luar biasa (KLB) wabah Ebola setelah otoritas kesehatan memastikan satu kasus galur Sudan yang relatif jarang ditemukan. Sebuah hasil penelitian mengungkap tim bubur tidak diaduk memiliki kecerdasan emosional lebih tinggi dibandingkan dengan tim bubur diaduk. Apa iya?

Penerimaan perpajakan dalam Rancangan Anggaran Pendapatan dan Belanja 2023 ditargetkan mencapai Rp2.016,9 triliun, tumbuh 4,8 persen dari outlook tahun 2022 sebesar Rp1.924,9 triliun.

I got a demo of RP1's single shard with 4000 users in mid-July, and then chatted with 3 team members in August to unpack their journey towards creating a scalable network architecture for the Metaverse. Their demo was built on WebXR, but it could be used on other game engines as well. There are real limitations on the client-side and VR hardware with how many of those 4000 users can been rendered within a close proximity, but having a single instance with hundreds or thousands of people could start to open up new use cases for cultivating virtual spaces that recreate some of the social dynamics of tech conferences, large-scale concerts, or perhaps persistant Burning Man playa communities that focus on serendipitious collisions and real-time hangouts. I unpack RP1's design process and potential implications of large-scale shards for the Metaverse with CEO Sean Mann, Chief Architect Dean Abramson, and Chief Client Architect Yin-Chien Yeap (aka Yinch).

In this episode we speak to Raul about his recent RP1 release with The Detent Escapement. His time at Parmigiani Fleurier and the process of creating a watch, from conception to production. 

"Aku melihat bahwa tidak ada yang lebih baik bagi manusia dari pada bergembira dalam pekerjaannya, sebab itu adalah bahagiannya." (Pengkhotbah 3:22a) Renungan: Seorang pemuda yang sedang lapar pergi ke sebuah warung di pinggiran jalan. Saat ia sedang makan, datanglah seorang anak kecil penjual kue menawarkan kue kepadanya, "Pak, mau beli kue?" Dengan ramah pemuda itu menjawab, "Tidak, saya sedang makan." Anak kecil tersebut tidak putus asa ketika tawaran pertamanya ditolak. Ia menawarkan lagi kue setelah pemuda itu selesai makan. Sang pemuda menjadi risih untuk menolak. Kemudian ia mengeluarkan uang Rp1.500,- dan memberikannya sebagai sedekah saja. Anak kecil itu lalu mengambil uang pemberian sang pemuda dan memberikannya kepada pengemis. Pemuda tadi bingung dan bertanya, "Mengapa kamu memberikan uang itu kepada pengemis?" Anak kecil penjual kue itu tersenyum lugu dan menjawab, "Saya sudah berjanji pada ibu saya untuk menjual kue ini, bukan untuk menjadi pengemis. Dan saya akan bangga pulang ke rumah bertemu ibu jika kue buatan Ibu terjual habis." Pemuda tersebut merasa kagum dengan kata-kata anak kecil itu dan akhirnya ia memborong semua kue yang dijual anak kecil tersebut. Ia melakukannya bukan karena kasihan tetapi karena prinsip yang dimilikinya. Bagaimana dengan kita, sudahkah kita memunyai cara pandang yang benar tentang profesi ataupun pekerjaan kita atau apakah kita hanya beranggapan bahwa bekerja hanyalah untuk memperoleh uang? Bila cara pandang dan sikap kita terhadap pekerjaan hanya untuk memeroleh uang, maka kita akan mudah bosan, menghalalkan segala cara dan tidak menghargai orang lain maupun pekerjaan kita. Namun bila kita menganggap bahwa pekerjaan kita adalah sebuah kehormatan dan anugerah yang diberikan oleh Tuhan untuk menjadi berkat bagi orang lain, maka kita akan memberikan yang terbaik dan bekerja dengan sepenuh hati. Jadi, apapun jenis pekerjaan yang kita lakukan saat ini, entah itu pekerjaan kecil ataupun pekerjaan besar, kerjakanlah dengan sepenuh hati dan kehormatan, karena orang yang bekerja tidak hanya untuk uang, justru akan dikejar-kejar oleh berkat dari Tuhan. Tuhan Yesus memberkati. Doa: Tuhan Yesus, terima kasih untuk pekerjaan yang saat ini Kau percayakan padaku. Bantulah aku untuk melakukannya dengan baik, sehingga apa yang kukerjakan pada akhirnya menjadi berkat bukan hanya untuk diriku saja, tetapi juga untuk banyak orang dan untuk kemuliaan nama-Mu. Amin. (Dod).

Ghozali mengguncang Indonesia ketika selfienya yang berbentuk NFTs (non-fungible tokens) dihargai Rp1,5 miliar. Dalam konteks lebih besar, dunia kini tengah mengalami tren NFTs dan cryptocurrency yang popularitasnya menanjak. Peran negara dalam sistem berbasis blockchain tersebut pun dipertanyakan. Apa untung-rugi sistem ini dari kacamata sosial-politik? Bagaimana tata kelola ruang siber (cyberspace) di dunia internasional? Apakah negara tidak lagi relevan? Simak analisis selengkapnya di Podcast Bebas Aktif! Instagram: @kontekstualcom Twitter: @kontekstualcom YouTube: Kontekstual Kunjungi kontekstual.com untuk berita HI paling aktual!

The Dow Family and The Dow Realty Company! Rich in tradition and Family Values. If you have ever met Jeff Dow, you would remember him. He is an extremely nice person, with a great family history, and certainly a giver,both in his profession and his community.  He continues the values and integrity of his family.  His business was built on honesty and hard work.  Dow Realty has a wonderful reputation dating back to 1983 when Jeff's dad, Robert E Dow founded the company it. Immediately, Bob's company had prominence in New Haven County and a great reputation.   He was well versed in the commercial real estate profession and had a great professional reputation. .Jeff Dow started with Dow Realty in 2008, continuing the great tradition of   Dow Realty.    In this video, Jeff shares with us, how the commercial real estate market works, what to look for when buying and , what to avoid. In this educational video Jeff discusses the in-depth analytics that areis needed when comparing property and evaluating as to whether it will create the ROI for an investor.[RP1]  can receive. from their investment in the property. Commercial real estate, as we learn from Jeff, is not like buying a home. If you are not careful, what seems like a great investment could end up being a nightmare. Jeff is a seasoned veteran and takes his education of his profession seriously. Jeff is a designee of the CCIM institute, a real estate designation held by only 6% of commercial real estate practitioners nationwide. You can reach Jeff at: Dow Realty Co. 943 Grand Ave. New Haven, CT 06511Cell: 203 –824-7760203-776-000Fax: 203-565-7707www.dowrealty.com

Thor, Stubbs, and Axryn host an RH community night AMA with a slew of community guests! This episode was almost lost as Stubbs didn't get his audio recorded, luckily he was crazy enough to re-record his parts from scratch. What ensues is pure madness, with a dash of reveals, GOTM, GOTY news, and even a sing-a-long! Lets go!Thanks to our patrons!Join our Patreon at https://patreon.com/RetroHandheldsJoin our Discord at https://discord.gg/RetroHandheldsBRB Theme by Choosh 

YouTuber JimRPG joins the gang on a wild ride through the handheld world, their favorite black friday deals, and many other topics we won't spoil for you with this silly summary. Happy turkey times, everyone!JimRPG on the internet: YouTube: https://youtube.com/c/JimRPGTwitter: @JimRPGDiscord: https://discord.gg/gXs9JhUtrkYouTube2: https://youtube.com/channel/UCWgiqwQCTOhXdq1JbEfJ63ATheme song by ChooshOur Discord: https://discord.gg/RetroHandhelds

Bill interviewed a few of the exhibitors at the 2021 SEMA show.Hawk Performance Brakes:Taylor Allen shares more information about Hawk and announces the new endurance racing brake pad.Hawk's InstagramEBC Brakes:Candice and Steve share more about EBC brakes.  We learn RP1 & RPX pads with floating discs and they tease us about a new release that will be announced at PRI. EBC Brakes InstagramRacingJunk.com:Ian Downey tells us more about RacingJunk.com services  and reminds us that it's a free site.  Buying or selling a race car, trailer, to rig has never been easier!Racing Junk InstagramOhlins:Brian Fowler tells us more about the products that Ohlins offers and reminds us that Ohlins was selected as the damper provider for  Next Gen NASCAR car.  He also shares a few new product launches.Ohlins Instagram NRG Innovations:Jason the VP at NRG Innovations talks about their affordable product lines for your daily driver and your track car.  They are releasing a new line of reclining seats and designer steering wheels.NRG InstagramBig Kids Garage:James Packer tells us more about his new project, Big Kids Garage.  He's a NASA racer and has a long history in motorsports.Big Kids Garage InstagramEssex Racing:Jack from Essex Racing which is the exclusive AP distributor in America talks about AP Racing's products which includes brake components and clutches.  He also discusses the selection of AP to part of the Next Gen NASCAR car.Essex Racing InstagramG-Force Racing Gear:Craig Robinson tells us all about what G-Force Racing has to offer and highlights their new helmet. We learn that a new suit, glove and  shoe line is coming out next year.  For this year there is the Super Nova T800, full carbon fiber helmet.G-Force Instagram

Nick and Single White Medusa talkCheck out Nick's book CTRL ALT Revolt!Christopher DiNote5.0 out of 5 stars This series is what Ready Player One could have been..Reviewed in the United States on October 31, 2019Verified PurchaseIn other words, actually great. Nick Cole pulls off an incredible synthesis of pop culture, Hollyweird (likely from personal experience), California (likely also from personal experience), big tech, action, satire (sometimes just a little bit too on the nose, but his targets are well deserving of some mockery, they've gotten off too easy in the past), gamer culture (more 1990s than 80s, but lots of retro goodies for those of us of a certain age), Star Trek, and the Terminator.Speaking of those two, this is very much a full-blown Star Trek novel, in the same way that Galaxy Quest was a Star Trek movie - the best one), and a Terminator story (the best since Alex Ross had his crack at it years and years ago). My one quibble is the corporate rah-rah at the end which I think gives them a little too much credit, but it does set up the sequels very, very well with a bit of irony, whether that is intentional or not.I was also struck that there's more than a little bit of Jerry Pournelle's CoDominion in there too, especially the early days stories captured in High Justice. Cole also seems to have three permanent features in any of his books that makes me wonder if there isn't a "Dark Tower" -esque metastructure at work: zombies, Terminators, and the apocalypse. Over and over again. I can't figure out if he's writing the world's greatest "fix" fanfic series of all time, or if something deeper at play.Synthesized together like this, it attains a far greater depth and perspective, sans nihilism and fatalism, than RP1. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit nickcole.substack.com/subscribe

In this episode, Amanda is on location in Tanzania while the boys hold down the fort! Join them as they talk about existing technologies found in RP1. --- Support this podcast: https://anchor.fm/the-virtual-reality-podcast/support